RX Biosyent Inc

BioSyent Inc. ("BioSyent")(TSX VENTURE:RX) today released a summary of its 2010
financial results. 


Total Sales were 63% higher at $1,681,210 in 2010 compared to $1,029,902 in 2009
driven primarily by growth in the pharmaceutical segment of the business. 


Gross Margins increased from 64.4% in 2009, to 73.5% in 2010 primarily because
of mix in favour of higher margin products. 


The Company earned a profit of $52,160 in 2010 which represented a significant
turn around of $312,717 versus the loss of ($260,557) in 2009. The 2010 full
year profit of $52,160 included one time costs of $62,589 incurred due to a June
2010 precautionary product recall.


Sales for the fourth quarter ending December 31, 2010 of $465,191 were 293%
higher than the sales in the corresponding quarter in 2009. This signifies a
greater contribution from the pharmaceutical business. Net income for the fourth
quarter ending December 31, 2010 was $84,147 compared to a loss of ($170,410) in
the fourth quarter of 2009. 


Full details of 2010 results including December 31, 2010 Financial Statements
and Management's Discussion & Analysis will be published in the company's 2010
Annual Report and will be posted on sedar.com on March 14, 2010. 


BioSyent Inc. continues to concentrate on its pharmaceutical strategy to source
products that have been successfully developed and proven to be safe and
effective; manage these products through the regulatory process and product
registration (approval); and once approved, market these products in Canada.
These pharmaceuticals will compete in both the branded and generic market
segments.


BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly
owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences
pharmaceutical products and markets these products in Canada. Wholly owned
BioSyent subsidiary Hedley Technologies Ltd. operates the company's legacy
business marketing bio and health friendly non-chemical insecticides. BioSyent
common shares are listed for trading on the TSX Venture Exchange (TSXV) under
the symbol RX.


This press release may contain information or statements that are
forward-looking.  The contents herein represent our judgment, as at the release
date, and are subject to risks and uncertainties that may cause actual results
or outcomes to be materially different from the forward-looking information or
statements.  Potential risks may include, but are not limited to, those
associated with clinical trials, product development, future revenue,
operations, profitability and obtaining regulatory approvals.

Biosyent (TSXV:RX)
Historical Stock Chart
From May 2024 to Jun 2024

Biosyent (TSXV:RX)
Historical Stock Chart
From Jun 2023 to Jun 2024